The Isosorbide‐Hydralazine Story: Is There a Case for Race‐Based Cardiovascular Medicine?
Key result
Isosorbide dinitrate and hydralazine reduce mortality ~43% in Black patients with moderate-to-severe HF.
- 43% reduction
- P=0.012
- n=1,050
Why the study?
Does isosorbide dinitrate and hydralazine improve outcomes in black patients with heart failure?
Population
Black patients with heart failure
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May inform therapy selection for black patients with heart failure; leaves open questions on genetic and socioeconomic confounders in race-based approaches.
Structured PICO
Does isosorbide dinitrate and hydralazine improve outcomes in black patients with heart failure?
P
Population
1,050 self-identified black patients with moderate-to-severe heart failure on standard therapy.
I
Intervention
Isosorbide dinitrate and hydralazine
Main Result
Effect estimate: 43% reduction
p-value: p=0.012
While the combination of isosorbide dinitrate and hydralazine shows significant clinical benefit in black patients with heart failure, the concept of race-based medicine remains controversial due to complex underlying genetic and socioeconomic confounders.
Limitations
- Race and ethnicity are not true biologic or genetic categories.
- Unmeasured variables such as socioeconomic status, sodium intake, obesity, and physical inactivity may confound race-based observations.
- Race and ethnicity are not true biologic or genetic categories
- Unmeasured variables such as socioeconomic status, sodium intake, obesity, and physical inactivity may confound results
Cite This Study
Keith C. Ferdinand (2006) conducted a review in Heart failure (n=1,050). Isosorbide dinitrate and hydralazine vs. Standard therapy was evaluated on Death (43% reduction, p=0.012). In self-identified black patients with moderate-to-severe heart failure, isosorbide dinitrate and hydralazine reduced death by 43% (P=0.012) and hospitalization by 39% (P<0.001).